Global Strategic Investment Solutions LLC Has $1.14 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Global Strategic Investment Solutions LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,841 shares of the medical research company’s stock after purchasing an additional 61 shares during the period. Global Strategic Investment Solutions LLC’s holdings in Thermo Fisher Scientific were worth $1,139,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Advisory Alpha LLC raised its stake in Thermo Fisher Scientific by 77.4% during the 1st quarter. Advisory Alpha LLC now owns 779 shares of the medical research company’s stock worth $453,000 after buying an additional 340 shares during the period. Advisory Services Network LLC increased its holdings in Thermo Fisher Scientific by 2.7% in the 1st quarter. Advisory Services Network LLC now owns 8,869 shares of the medical research company’s stock worth $5,155,000 after acquiring an additional 231 shares during the last quarter. CFO4Life Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth $234,000. Empirical Finance LLC increased its position in shares of Thermo Fisher Scientific by 3.4% during the first quarter. Empirical Finance LLC now owns 14,143 shares of the medical research company’s stock valued at $8,220,000 after buying an additional 467 shares during the period. Finally, Envestnet Portfolio Solutions Inc. grew its position in Thermo Fisher Scientific by 30.2% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 45,451 shares of the medical research company’s stock worth $26,417,000 after buying an additional 10,547 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.2 %

TMO traded down $1.03 during trading hours on Thursday, hitting $558.65. 130,802 shares of the company’s stock were exchanged, compared to its average volume of 1,454,915. The firm has a 50 day moving average of $596.33 and a 200 day moving average of $583.80. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $437.26 and a 12-month high of $627.88. The firm has a market cap of $213.68 billion, a P/E ratio of 35.09, a price-to-earnings-growth ratio of 3.67 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. During the same quarter last year, the company posted $5.69 earnings per share. The business’s quarterly revenue was up .2% compared to the same quarter last year. Analysts predict that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on TMO shares. TD Cowen increased their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Stephens began coverage on Thermo Fisher Scientific in a research report on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 price objective on the stock. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Redburn Atlantic initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,850 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the sale, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,611,804.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Marc N. Casper sold 5,850 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $557.89, for a total transaction of $3,263,656.50. Following the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at approximately $67,611,804.88. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the completion of the transaction, the chief executive officer now directly owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,150 shares of company stock valued at $10,094,925 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.